# Contraceptives/Protectives — company-by-company sector analysis > Contraceptives/Protectives: Cupid Ltd owns the largest revenue base AND the fastest current growth. Sector Alpha — machine-written from the numbers. Data as of 2026-08-15. Not investment advice. ## Bottom line Contraceptives/Protectives has outperformed NIFTY 500 by 429.9% over 52 weeks and 41.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 1 of 1 beat the sector itself. Cupid Ltd leads with revenue of ₹453 crore, based on 1 of 2 comparable companies through Jun 2026. ## Sector relative strength Contraceptives/Protectives has outperformed NIFTY 500 by 429.9% over the last 52 weeks. Over 13 weeks the gap is a lead of 41.6%. 1 of 1 covered company currently beats NIFTY on Mansfield relative strength, so leadership inside the sector is broad. Cupid Ltd is the strongest against the sector itself at +38.7%. Readings are as of 2026-08-09. 13-week sector return versus NIFTY 500: 42% 52-week sector return versus NIFTY 500: 430% Stocks leading NIFTY: 1/1 Stocks leading sector: 1/1 Central tension: The central tension: current leadership is concentrated, so durability matters more than rank. Companies: 2 Combined market value: ₹37.1K Cr ## 4-Factor Sector Score An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment. 1. Cupid Ltd (CUPID): 89/100 — Sector-leading setup; evidence 90% - Growth & earnings 35.0/35 | Capital efficiency 20.0/25 | Valuation 13.7/20 | Relative strength 20.0/20 - Price stage: LEADER — Ahead of the benchmark 13 weeks or more running, and ahead over the past year. - Led NIFTY 500 by 5%+ over the prior 13 weeks in 12 of the last 12 weeks - Exact sum: 35 + 20 + 13.7 + 20 = 88.7 - Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. 2. Anondita Medicare Ltd (ANONDITA): 59/100 — Thin evidence · provisional; evidence 33% - Growth & earnings 17.7/35 | Capital efficiency 21.5/25 | Valuation 10.0/20 | Relative strength 10.0/20 - Price stage: FADING — Was leading by 5% or more four weeks ago and is not now. - Led NIFTY 500 by 5%+ over the prior 13 weeks in 10 of the last 12 weeks - Exact sum: 17.7 + 21.5 + 10 + 10 = 59.2 - Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. ## Market action Cupid Ltd has the strongest one-year price move in Contraceptives/Protectives at +729.6%. It also leads on Mansfield relative strength against NIFTY at +156.9%. 1 of 1 covered company is above zero on that measure. Every line covers 313 weekly closes through 2026-08-07. ### Strongest one-year price performers 1. Cupid Ltd (CUPID): 730% ### Strongest relative strength versus NIFTY 500 1. Cupid Ltd (CUPID): 157% ## Revenue Scale & Growth Durability What the numbers say: Cupid Ltd is the scale leader at ₹453 crore, Cupid Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 122.1% from a ₹453 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale. Investor read: Cupid Ltd is the scale benchmark; Cupid Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns. This conclusion weakens if: Cupid Ltd's growth falls below Cupid Ltd's for two consecutive comparable reports while operating margin also compresses. Evidence: Cupid Ltd · ₹453 crore | Not enough peers | 7/8 recent comparable periods | 1/2 companies · 24 observations Definition: Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress. ### Revenue — largest 1. Cupid Ltd (CUPID): ₹453 Cr ### Revenue growth — fastest growers 1. Cupid Ltd (CUPID): 100% ### 20-quarter Revenue history - CUPID: Sep 2021 ₹34 Cr | Dec 2021 ₹37 Cr | Mar 2022 ₹31 Cr | Jun 2022 ₹31 Cr | Sep 2022 ₹45 Cr | Dec 2022 ₹43 Cr | Mar 2023 ₹42 Cr | Jun 2023 ₹35 Cr | Sep 2023 ₹36 Cr | Dec 2023 ₹40 Cr | Mar 2024 ₹63 Cr | Jun 2024 ₹39 Cr | Sep 2024 ₹42 Cr | Dec 2024 ₹46 Cr | Mar 2025 ₹56 Cr | Jun 2025 ₹60 Cr | Sep 2025 ₹84 Cr | Dec 2025 ₹94 Cr | Mar 2026 ₹120 Cr | Jun 2026 ₹155 Cr - ANONDITA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 ₹31 Cr | Dec 2024 — | Mar 2025 ₹46 Cr | Jun 2025 — | Sep 2025 ₹54 Cr | Dec 2025 — | Mar 2026 ₹83 Cr | Jun 2026 — ### 20-quarter Revenue growth history - CUPID: Sep 2021 — | Dec 2021 — | Mar 2022 -26% | Jun 2022 -8.8% | Sep 2022 32% | Dec 2022 16% | Mar 2023 35% | Jun 2023 13% | Sep 2023 -20% | Dec 2023 -7.0% | Mar 2024 50% | Jun 2024 11% | Sep 2024 17% | Dec 2024 15% | Mar 2025 -11% | Jun 2025 54% | Sep 2025 100% | Dec 2025 104% | Mar 2026 114% | Jun 2026 158% - ANONDITA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 74% | Dec 2025 — | Mar 2026 80% | Jun 2026 — ## Operating Economics & Margin Trend What the numbers say: Cupid Ltd leads both opm at 39% and margin change at +11 percentage points. Investor read: Cupid Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it. This conclusion weakens if: The next two comparable reports reverse the current margin change signal. Evidence: Cupid Ltd · 39% | 2.6% versus #2 · Anondita Medicare Ltd | 6/8 recent comparable periods | 2/2 companies · 24 observations Definition: Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth. ### OPM — highest 1. Cupid Ltd (CUPID): 39% 2. Anondita Medicare Ltd (ANONDITA): 38% ### Margin change — fastest expanders 1. Cupid Ltd (CUPID): +11.0 pp 2. Anondita Medicare Ltd (ANONDITA): +3.0 pp ### 20-quarter OPM history - CUPID: Sep 2021 20% | Dec 2021 12% | Mar 2022 18% | Jun 2022 17% | Sep 2022 25% | Dec 2022 33% | Mar 2023 26% | Jun 2023 9.0% | Sep 2023 20% | Dec 2023 30% | Mar 2024 49% | Jun 2024 17% | Sep 2024 25% | Dec 2024 25% | Mar 2025 24% | Jun 2025 28% | Sep 2025 34% | Dec 2025 37% | Mar 2026 31% | Jun 2026 39% - ANONDITA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 31% | Dec 2024 — | Mar 2025 35% | Jun 2025 — | Sep 2025 35% | Dec 2025 — | Mar 2026 38% | Jun 2026 — ### 20-quarter Margin change history - CUPID: Sep 2021 −12.8 pp | Dec 2021 −15.8 pp | Mar 2022 −3.7 pp | Jun 2022 −8.3 pp | Sep 2022 +5.0 pp | Dec 2022 +21.0 pp | Mar 2023 +7.7 pp | Jun 2023 −7.7 pp | Sep 2023 −5.0 pp | Dec 2023 −3.0 pp | Mar 2024 +23.0 pp | Jun 2024 +8.0 pp | Sep 2024 +5.0 pp | Dec 2024 −5.0 pp | Mar 2025 −25.0 pp | Jun 2025 +11.0 pp | Sep 2025 +9.0 pp | Dec 2025 +12.0 pp | Mar 2026 +7.0 pp | Jun 2026 +11.0 pp - ANONDITA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 +4.0 pp | Dec 2025 — | Mar 2026 +3.0 pp | Jun 2026 — ## Profit Scale & Acceleration What the numbers say: Cupid Ltd leads with ₹137 crore of TTM profit, Cupid Ltd shows ≥100% on the scoring scale (185.4% uncapped) growth from a ₹137 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale. Investor read: Cupid Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it. This conclusion weakens if: The next two comparable reports reverse the current profit growth signal. Evidence: Cupid Ltd · ₹137 crore | Not enough peers | 7/8 recent comparable periods | 1/2 companies · 24 observations Definition: Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank. ### Net profit — largest 1. Cupid Ltd (CUPID): ₹137 Cr ### Profit growth — fastest growers 1. Cupid Ltd (CUPID): 100% ### 20-quarter Net profit history - CUPID: Sep 2021 ₹4 Cr | Dec 2021 ₹2 Cr | Mar 2022 ₹5 Cr | Jun 2022 ₹5 Cr | Sep 2022 ₹9 Cr | Dec 2022 ₹10 Cr | Mar 2023 ₹8 Cr | Jun 2023 ₹2 Cr | Sep 2023 ₹5 Cr | Dec 2023 ₹9 Cr | Mar 2024 ₹24 Cr | Jun 2024 ₹8 Cr | Sep 2024 ₹10 Cr | Dec 2024 ₹11 Cr | Mar 2025 ₹12 Cr | Jun 2025 ₹15 Cr | Sep 2025 ₹24 Cr | Dec 2025 ₹33 Cr | Mar 2026 ₹36 Cr | Jun 2026 ₹44 Cr - ANONDITA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 ₹6 Cr | Dec 2024 — | Mar 2025 ₹10 Cr | Jun 2025 — | Sep 2025 ₹13 Cr | Dec 2025 — | Mar 2026 ₹21 Cr | Jun 2026 — ### 20-quarter Profit growth history - CUPID: Sep 2021 — | Dec 2021 — | Mar 2022 -17% | Jun 2022 -17% | Sep 2022 125% | Dec 2022 400% | Mar 2023 60% | Jun 2023 -60% | Sep 2023 -44% | Dec 2023 -10% | Mar 2024 200% | Jun 2024 300% | Sep 2024 100% | Dec 2024 22% | Mar 2025 -50% | Jun 2025 88% | Sep 2025 140% | Dec 2025 200% | Mar 2026 200% | Jun 2026 193% - ANONDITA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 117% | Dec 2025 — | Mar 2026 110% | Jun 2026 — ## Return On Capital Employed What the numbers say: Anondita Medicare Ltd leads ROCE at 43.6%, 10.1 percentage points above Cupid Ltd. Cupid Ltd has the strongest latest improvement at +13 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability. Investor read: Anondita Medicare Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it. This conclusion weakens if: The next two comparable reports reverse the current roce change signal. Evidence: Anondita Medicare Ltd · 43.6% | 30.1% versus #2 · Cupid Ltd | Not enough history | 2/2 companies · 18 observations Definition: ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability. ### ROCE — highest 1. Anondita Medicare Ltd (ANONDITA): 44% 2. Cupid Ltd (CUPID): 34% ### ROCE change — fastest improvers 1. Cupid Ltd (CUPID): +13.0 pp 2. Anondita Medicare Ltd (ANONDITA): −18.0 pp ### 20-quarter ROCE history - CUPID: Sep 2021 22% | Dec 2021 19% | Mar 2022 14% | Jun 2022 — | Sep 2022 16% | Dec 2022 — | Mar 2023 23% | Jun 2023 — | Sep 2023 16% | Dec 2023 20% | Mar 2024 16% | Jun 2024 26% | Sep 2024 18% | Dec 2024 29% | Mar 2025 11% | Jun 2025 21% | Sep 2025 17% | Dec 2025 32% | Mar 2026 24% | Jun 2026 — - ANONDITA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 23% | Dec 2025 — | Mar 2026 32% | Jun 2026 — ### 20-quarter ROCE change history - CUPID: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −6.1 pp | Dec 2022 — | Mar 2023 +8.5 pp | Jun 2023 — | Sep 2023 −0.1 pp | Dec 2023 — | Mar 2024 −6.9 pp | Jun 2024 — | Sep 2024 +1.5 pp | Dec 2024 +9.6 pp | Mar 2025 −5.1 pp | Jun 2025 −5.8 pp | Sep 2025 −1.0 pp | Dec 2025 +2.8 pp | Mar 2026 +13.0 pp | Jun 2026 — ## Valuation Against Growth & Quality What the numbers say: Cupid Ltd has the lowest comparable PEG at 0.96×. Only 1 of 2 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree. Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy. This conclusion weakens if: The next two comparable reports reverse the current p/e signal. Evidence: Cupid Ltd · 0.96× | Not enough peers | 0/8 recent comparable periods | 1/2 companies · 2 observations Definition: PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing. ### PEG — lowest PEG 1. Cupid Ltd (CUPID): 1.0 ### P/E — lowest P/E 1. Anondita Medicare Ltd (ANONDITA): 56.3 2. Cupid Ltd (CUPID): 257.0 ### 20-quarter PEG history - CUPID: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 2.7 | Mar 2024 — | Jun 2024 — | Sep 2024 1.0 | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 — ### 20-quarter P/E history - CUPID: Sep 2021 10.4 | Dec 2021 10.1 | Mar 2022 16.6 | Jun 2022 15.1 | Sep 2022 16.7 | Dec 2022 19.7 | Mar 2023 18.0 | Jun 2023 18.0 | Sep 2023 29.2 | Dec 2023 80.1 | Mar 2024 110.5 | Jun 2024 60.7 | Sep 2024 55.7 | Dec 2024 40.7 | Mar 2025 33.3 | Jun 2025 71.3 | Sep 2025 139.1 | Dec 2025 309.2 | Mar 2026 136.4 | Jun 2026 228.2 - ANONDITA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 29.8 | Dec 2025 — | Mar 2026 55.4 | Jun 2026 — ## What can make this comparison misleading? - A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason. - A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment. - The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed. - An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion. - 1 company draws at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; it is marked unverified wherever that figure appears. - Thin comparisons: Revenue, Net profit, Valuation have fewer than three usable current readings. ## Every company - Cupid Ltd (CUPID) — market value ₹35.2K Cr; latest fundamentals Jun 2026 - Anondita Medicare Ltd (ANONDITA) — market value ₹1.9K Cr; latest fundamentals Mar 2026; includes UNVERIFIED second-feed figures ## Source standing of each company Cross-checked: 1. Unverified: 1. Withheld: 0. Graded companies: 2. 1 of 2 companies draws at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear. - UNVERIFIED | ANONDITA | Anondita Medicare Ltd | too little overlapping reported history to cross-check the second feed ## Methodology and freshness Fundamentals through Jun 2026; prices through 2026-08-07. Up to 20 quarters per company. Reported history is normalized to Indian rupees crore. Missing values are not interpolated. Derived metrics are calculated only when their inputs are comparable. ## Frequently asked questions ### Is the Contraceptives/Protectives sector outperforming NIFTY 500? Contraceptives/Protectives has outperformed NIFTY 500 by 429.9% over 52 weeks and 41.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 1 of 1 beat the sector itself. ### Which Contraceptives/Protectives company is largest by revenue? Cupid Ltd leads with revenue of ₹453 crore, based on 1 of 2 comparable companies through Jun 2026. ### Which Contraceptives/Protectives company is growing fastest? Cupid Ltd has the fastest current revenue growth at 100%, across 1 of 2 comparable companies. ### Which Contraceptives/Protectives company has the strongest 4-Factor Sector Score? Cupid Ltd ranks first at 88.7/100 with 90% evidence confidence. The score prioritizes research; it is not a buy recommendation. ### Which Contraceptives/Protectives company has the lowest comparable PEG? Cupid Ltd has the lowest comparable PEG at 0.96, among 1 of 2 companies whose earnings and growth are steady enough for the ratio to mean anything. ### How much history does this Contraceptives/Protectives comparison include? The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated. ### How is the 4-Factor Sector Score calculated? The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral. ### Is there a Nifty Contraceptives/Protectives index? NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Contraceptives/Protectives, this page builds its own equal-weight basket of 2 listed Contraceptives/Protectives companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026. ### Which are the best Contraceptives/Protectives stocks in India? Ranked by this page's four-factor score, Cupid Ltd places first among 2 listed Contraceptives/Protectives companies, followed by Anondita Medicare Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser. ### How many Contraceptives/Protectives stocks are listed in India? This comparison covers 2 listed Contraceptives/Protectives companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026. ### Which Contraceptives/Protectives company is the biggest? Cupid Ltd is the largest, with trailing-twelve-month revenue of ₹453 crore. That covers 1 of 2 companies with comparable reporting through Jun 2026. ### Which Contraceptives/Protectives company has the best profit margins? Cupid Ltd has the highest operating margin at 39%, from 2 of 2 comparable companies. Cupid Ltd shows the biggest recent improvement, at +11 percentage points. A high margin matters most when it is holding or rising, not when it is peaking. ### Which Contraceptives/Protectives company makes the most profit? Cupid Ltd earns the most, at ₹137 crore of trailing-twelve-month net profit, from 1 of 2 comparable companies. Cupid Ltd has the fastest profit growth at the ≥100% scoring cap, though growth off a small or recovering profit base overstates how much has actually changed. ### Which Contraceptives/Protectives company earns the highest return on capital? Anondita Medicare Ltd leads on return on capital employed at 43.6%, across 2 of 2 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year. ### Which Contraceptives/Protectives stock is the cheapest? On PEG — where a LOWER number is cheaper — Cupid Ltd screens cheapest at 0.96×. Only 1 of 2 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own. ### Is the Contraceptives/Protectives sector beating the market? Contraceptives/Protectives has outperformed NIFTY 500 by 429.9% over the last 52 weeks and 41.6% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it. ### Which Contraceptives/Protectives stock has the strongest price momentum? Cupid Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all. ### Which Contraceptives/Protectives company scores highest for research priority? Cupid Ltd scores 88.7 out of 100 with 90% evidence confidence, from 35 points on growth and earnings, 20 on capital efficiency, 13.7 on valuation and 20 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research. ### How many Contraceptives/Protectives companies does this comparison cover, and over what period? It compares 2 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data. ### What is the total market cap of the Contraceptives/Protectives sector? The 2 Contraceptives/Protectives companies on this page carry ₹37,130 crore of combined market value. Cupid Ltd is the largest at ₹35,248 crore, about 95% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-15. ### How is the Contraceptives/Protectives sector performing? 1 of the 1 covered Contraceptives/Protectives companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 429.9% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-15. ### Why are some values on this page blank? A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad. ### Is this investment advice? No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.